Theralase(R) Closes $1.1 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-03-10 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
King of Prussia, Pennsylvania--(Newsfile Corp. - March 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-10 7:00 AM EDT | Phio Pharmaceuticals Corp.
Adia Med Unveils a Fresh Facelift: New Website by ZenChange Marketing Spotlights Cutting-Edge Regenerative Medicine Studies
Orlando, Florida--(Newsfile Corp. - March 9, 2026) - Adia Nutrition's (OTCQB: ADIA) subsidiary, Adia Med, has launched a complete digital refresh of its online presence. Through a strategic partnership with ZenChange Marketing, Adia Med has relaunched its website with a modern, streamlined design focused on transparency, accessibility, and clear information about its investigational studies. The update makes it easier for families, researchers, and healthcare professionals to explore the orga
Healthcare and Hospitals, Health
2026-03-09 9:38 AM EDT | Adia Nutrition Inc.
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to present its latest preclinical data demonstrating that X-Ray-activated Rutherrin® is effective in th
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-03-09 7:00 AM EDT | Theralase Technologies Inc.
HEALWELL AI to Announce Fourth Quarter and Year End 2025 Financial Results on March 19, 2026
Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce the Company will release its Fiscal Fourth Quarter and Year End 2025 financial results for
Technology, Healthcare and Hospitals
2026-03-09 3:15 AM EDT | HEALWELL AI
Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
Ad hoc announcement pursuant to Art. 53 LR Full Year 2025 revenue of €104.2 million, in line with guidance, with 85% recurring revenues Recurring revenues of €88.1 million, +15% year-over-year, reflecting structural business transformation EBITDA of €9.5 million, exceeding the upper end of guidance
Healthcare and Hospitals, Health
2026-03-09 2:00 AM EDT | Cosmo Pharmaceuticals N.V.
TGI Solar Power Group (TSPG) Signs LOI to Acquire XGC Corp to Build National Carbon Registries Under Paris Agreement Article 6.4
Florida and Toronto, Ontario--(Newsfile Corp. - March 6, 2026) - TGI Solar Power Group, Inc. (OTC: TSPG), a diversified sustainable infrastructure and clean-energy technology holding company, today announced it has signed a Letter of Intent (LOI) to acquire XGC Corp, an Ontario-based developer of sovereign-grade carbon registry infrastructure powered by artificial intelligence, blockchain technology, and enterprise financial systems. The proposed transaction
Technology, Healthcare and Hospitals
2026-03-06 5:30 PM EST | XGC Software Inc.
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeuti
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-05 4:05 PM EST | Phio Pharmaceuticals Corp.
AliMed Launches New Line of Lightweight Hybrid Gel-Foam Positioners Aimed at Improving Safety for Patients and Staff
Dedham, Massachusetts--(Newsfile Corp. - March 5, 2026) - AliMed, LLC, a Massachusetts-based medical device manufacturer and distributor, is introducing its own line of innovative hybrid gel-foam positioners, expanding its broad portfolio of patient positioners. This unique design delivers the benefits of all-gel positioners with up to 50% reduction in weight. These new positioners are being sold under the name AliBlue™ L
Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-05 10:00 AM EST | AliMed, LLC
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-05 7:00 AM EST | Phio Pharmaceuticals Corp.
HEALWELL AI Announces Multi-Million Dollar U.S. Health Information Exchange Contract and AI-Driven Pipeline Momentum
HEALWELL has signed a multi-million dollar, multi-year U.S.-based Health Information Exchange (HIE) software contract following a competitive procurement process. Strong momentum in all parts of the software pipeline including renewals, extensions, short listing and intent to award have advanced across core markets, reinforcing recurring data infrastructure revenue. Increasing participation in coordinated, enterprise-scale RFP bids leveraging Orion Health's global footpri
Technology, Healthcare and Hospitals
2026-03-05 3:15 AM EST | HEALWELL AI
Cosmo Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus
Dublin, Ireland--(Newsfile Corp. - March 5, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an artificial intelligence (AI)-based computer-aided detection (CADe) system for the identification of early neoplasia in Barrett’s esophagus. The collaboration represents an important step in ex
Healthcare and Hospitals, Health
2026-03-05 1:00 AM EST | Cosmo Pharmaceuticals N.V.
CareRx Announces Q1 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - March 4, 2026) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company"), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, today announced that the Company's Board of Directors has declared a dividend of CAD$0.02 per outstanding common share of the Company ("Common Shares"), payable on April 9, 2026, to holders of record of Common Shares as of the close
2026-03-04 7:42 PM EST | CareRx Corporation
CareRx Reports 2025 Year-End and Fourth Quarter Results
Toronto, Ontario--(Newsfile Corp. - March 4, 2026) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company"), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Highlights for the Year and Fourth Quarter of 2025 Average Beds Serviced1 in the fourth quarter of 2
2026-03-04 7:40 PM EST | CareRx Corporation
Adia Nutrition Announces Submission of Final Revised Protocol for Lower Back Pain Study with AdiaVita
Winter Park, Florida--(Newsfile Corp. - March 3, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a company focused on regenerative medicine and therapeutic solutions, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted its final revised protocol to the Institutional Review Board (IRB) for the lower back pain clinical study.
Healthcare and Hospitals, Health
2026-03-03 10:20 AM EST | Adia Nutrition Inc.
Canadian Pulmonary Fibrosis Foundation: Oxygen Therapy Saves Lives and Health Care Dollars
Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - Oxygen therapy is a lifeline for people living with chronic lung diseases like pulmonary fibrosis. It reduces hospitalizations and improves quality of life. Yet across Canada, access to medically necessary oxygen therapy depends on where a person lives, inconsistent qualification criteria and, in some cases, one's ability to pay. The Canadian Pulmonary Fibrosis Foundation (CPFF) is calling on health authorities to designate supplemental oxy
Healthcare and Hospitals, Health
2026-03-03 9:21 AM EST | Canadian Pulmonary Fibrosis Foundation
Conexeu Sciences Appoints Jean-Romain (JR) Falconnet as Head of Business Development & Licensing
Reno, Nevada--(Newsfile Corp. - March 2, 2026) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a biotechnology innovator redefining regenerative medicine through a next-generation extracellular matrix platform, is pleased to announce Jean-Romain (JR) Falconnet as Head of Business Development & Licensing. In his role at Conexeu, JR will lead business development, licensing strategy, and strategic partnerships—supporting the company's growth roadmap and expanding op
Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-02 9:03 AM EST | Conexeu Sciences Inc.
Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy
Toronto, Ontario--(Newsfile Corp. - March 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that recent in vitro data demonstrates an enhanced bladder cancer cell kill, when light-activated Ruvidar®
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-03-02 7:00 AM EST | Theralase Technologies Inc.
HEALWELL to Participate in Upcoming TD Cowen, Scotiabank and ROTH Investor Conferences
Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - HEALWELL AI Inc.(TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care
Technology, Healthcare and Hospitals
2026-02-27 7:00 AM EST | HEALWELL AI
New National Polling Shows Strong Support for Prevention-Focused Dental Hygiene Care While Gaps in Access to Care Persist
Ottawa, Ontario--(Newsfile Corp. - February 26, 2026) - New national public opinion research released today by the Canadian Dental Hygienists Association (CDHA) shows Canadians place exceptionally high trust in dental hygienists and strongly support prevention-focused dental hygiene care, while also acknowledging that barriers to access remain. The polling, conducted by Abacus Data, found that 96 per cent of Canadians hold a positive impression of dental hygienists, with more than eight in te
Healthcare and Hospitals, Health
2026-02-26 9:40 AM EST | Canadian Dental Hygienists Association